BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27240832)

  • 1. Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.
    Hyrenius-Wittsten A; Sturesson H; Bidgoli M; Jonson T; Ehinger M; Lilljebjörn H; Scheding S; Andersson AK
    Genes Chromosomes Cancer; 2016 Nov; 55(11):847-54. PubMed ID: 27240832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
    Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
    Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype.
    Huh YO; Tang G; Talwalkar SS; Khoury JD; Ohanian M; Bueso-Ramos CE; Abruzzo LV
    Cancer Genet; 2016; 209(7-8):313-20. PubMed ID: 27318442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
    Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S
    Haematologica; 2007 Jun; 92(6):744-52. PubMed ID: 17550846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H
    Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
    Wang SA; Jabbar K; Lu G; Chen SS; Galili N; Vega F; Jones D; Raza A; Kantarjian H; Garcia-Manero G; McDonnell TJ; Medeiros LJ
    Leukemia; 2010 Apr; 24(4):740-7. PubMed ID: 20072149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Sakhdari A; Tang Z; Ok CY; Bueso-Ramos CE; Medeiros LJ; Huh YO
    Cancer Genet; 2019 Oct; 238():18-22. PubMed ID: 31425921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review.
    Zhao M; Sun J; Liu S; Fan H; Fu Y; Tan Y; Gao S
    J Int Med Res; 2021 May; 49(5):3000605211018426. PubMed ID: 34057843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delineation of Molecular Lesions in Acute Myeloid Leukemia Patients at Diagnosis: Integrated Next Generation Sequencing and Cytogenomic Studies.
    Papuc SM; Erbescu A; Cisleanu D; Ozunu D; Enache C; Dumitru I; Lupoaia Andrus E; Gaman M; Popov VM; Dobre M; Stanca O; Angelescu S; Berbec N; Colita A; Vladareanu AM; Bumbea H; Arghir A
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34070898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA sequencing reveals a unique fusion of the lysine (K)-specific methyltransferase 2A and smooth muscle myosin heavy chain 11 in myelodysplastic syndrome and acute myeloid leukemia.
    Sanders MA; Kavelaars FG; Zeilemaker A; Al Hinai AS; Abbas S; Beverloo HB; van Lom K; Valk PJ
    Haematologica; 2015 Jan; 100(1):e1-3. PubMed ID: 25552680
    [No Abstract]   [Full Text] [Related]  

  • 12. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.
    Mann KP; DeCastro CM; Liu J; Moore JO; Bigner SH; Traweek ST
    Am J Clin Pathol; 1997 Jun; 107(6):653-60. PubMed ID: 9169661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes.
    Tsai HK; Gibson CJ; Murdock HM; Davineni P; Harris MH; Wang ES; Gondek LP; Kim AS; Nardi V; Lindsley RC
    Blood Adv; 2022 Jul; 6(14):4236-4240. PubMed ID: 35584376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
    Vetro C; Haferlach T; Meggendorfer M; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2020 Jan; 240():15-22. PubMed ID: 31698332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).
    Sun QY; Ding LW; Tan KT; Chien W; Mayakonda A; Lin DC; Loh XY; Xiao JF; Meggendorfer M; Alpermann T; Garg M; Lim SL; Madan V; Hattori N; Nagata Y; Miyano S; Yeoh AE; Hou HA; Jiang YY; Takao S; Liu LZ; Tan SZ; Lill M; Hayashi M; Kinoshita A; Kantarjian HM; Kornblau SM; Ogawa S; Haferlach T; Yang H; Koeffler HP
    Leukemia; 2017 Jan; 31(1):1-10. PubMed ID: 27389053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones.
    Saeed BR; Manta L; Raffel S; Pyl PT; Buss EC; Wang W; Eckstein V; Jauch A; Trumpp A; Huber W; Ho AD; Lutz C
    Int J Cancer; 2021 Jun; 148(11):2825-2838. PubMed ID: 33411954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IS THE AMPLIFICATION OF c-MYC, MLL AND RUNX1 GENES IN AML AND MDS PATIENTS WITH TRISOMY 8, 11 AND 21 A FACTOR FOR A CLONAL EVOLUTION IN THEIR KARYOTYPE?
    Angelova S; Spassov B; Nikolova V; Christov I; Tzvetkov N; Simeonova M
    Tsitol Genet; 2015; 49(3):25-32. PubMed ID: 26214902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
    He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
    Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.